QUE Oncology, Inc. Announces Positive Phase 1 Results with Q-122
Tags:
Phase 1
Oncology
Breast Cancer
Compound targets hot flashes in women receiving breast cancer therapy
ATLANTA--(BUSINESS WIRE)--A Phase I clinical study has found positive results with a compound aimed at treating hot flashes in women receiving anti-estrogen therapy for breast cancer. Q-122, developed for the treatment of vasomotor symptoms in women treated with hormone-blocking therapy, is the lead compound of QUE Oncology, Inc., a biotechnology company formed by Emory University and The University of Queensland’s commercialization company UniQuest in Brisbane, Australia.
Women taking estrogen-blocking drugs have few options to treat the debilitating hot flashes that often occur as a result of their treatment. Hot flashes were reduced by nearly 60 percent among study participants. A number of subjects experienced a complete response, having their hot flashes decrease from more than 50 per week to zero.
Study Q-1001 was “A Single Center, Two Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Effect on Vasomotor Symptoms of Q-122 in Female Subjects with Breast Cancer and Receiving an Aromatase Inhibitor or Tamoxifen”. Sixteen subjects received oral doses of Q-122 of 100 mg daily or 200 mg daily for 28 days.
“These study results are exciting, especially with a non-hormonal drug candidate, and they position us well to move into a dose-defining Phase 2 study in this patient population,” says Wendy Painter, MD, MPH, chief executive officer of QUE Oncology.
QUE Oncology is focused on preventing and treating life-threatening cancers and related conditions with therapies that have fewer side effects, thereby improving quality of life while providing a greater chance of recovery. QUE Oncology has well-developed research assets with a rich pre-clinical pipeline of cancer therapeutics.
Contacts
QUE OncologyDr. Painter, 919-619-1653http://QUEOncology.com
QUE OncologyDr. Painter, 919-619-1653http://QUEOncology.com
